National Academy of Sciences, Engineering, and Medicine, The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research (Washington, D.C.: The National Academies Press, 2017): at 1, 10.
K.Schwartz, Deputy Dir. & Chief Counsel, Cal. Dep't of Pub. Health, Address, Public Health Law Summit 2017 — Western Region (March 24, 2017).
12.
A.Roth, “The Uneasy Case for Marijuana as Chemical Impairment Under a Science-Based Jurisprudence of Dangerousness,”California Law Review103, no. 4 (2015): 841-917, at 870-73.
13.
61A C.J.S. Motor Vehicles §§ 1575, 1577 (2016).
14.
F. K.Whited, “Under the Influence/Impairment,” in Drinking/Driving Litigation: Criminal and Civil (2016): at § 2:10.
15.
See Roth, supra note 12, at 849-51.
16.
9 American Jurisprudence Proof of Facts 3D 459 §§ 5, 12-13 (1990).
C. H.Hall, Annotation, “Validity, Construction, and Application of Statutes Directly Proscribing Driving with Blood-Alcohol Level in Excess of Established Percentage,” 54American Law Reports 4th 149 (1987): at § 2(a).
See The Health Effects of Cannabis and Cannabinoids, supra note 6, at 184-185.
42.
P.Armentano, “Should Per Se Limits Be Imposed For Cannabis? Equating Cannabinoid Blood Concentrations with Actual Driver Impairment: Practical Limitations and Concerns,”Humboldt Journal of Social Relations35, no. 35 (2013): 45-55, at 47.
Id.; see The Health Effects of Cannabis and Cannabinoids, supra note 6, at 182-185.
46.
P.Sharma, P.Murthy, and M. M. SrinivasBharath, “Chemistry, Metabolism, and Toxicology of Cannabis: Clinical Implications,”Iranian Journal of Psychiatry7, no. 4 (2012): 149-156, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570572/> (last visited June 5, 2017); M. A. Huestis, “Human Cannabinoid Pharmacokinetics,” Chemical Biodiversity 4, no. 8 (2009): 1770-1804, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689518/> (last visited June 5, 2017).
47.
See Drugs and Human Performance Fact Sheets, supra note 44.
48.
See Roth, supra note 12, at 884-87.
49.
See Drugs and Human Performance Fact Sheets, supra note 44; Armentano, supra note 42, at 47-49.
50.
See Armentano, supra note 42, at 48; Roth, supra note 12, at 885-886.
51.
See Armentano, supra note 42, at 48.
52.
See National Institute on Drug Abuse, supra note 39.
See Governors Highway Safety Association, supra note 33.
60.
21 U.S.C.A. § 812.
61.
“Applications to Become Registered Under the Controlled Substances Act to Manufacture Marijuana to Supply Researchers in the United States,” 81 Federal Register 53846 (Aug. 12, 2016).